8 minute read
Sep. 21, 2023

An Azetidine-Containing, First-in-Class CCR4 Candidate with a 72 h Human Half-life


oral CCR4 antagonist Ph. II for immunooncology, 100 mg QD from optimization of prior CCR4 ligands J. Clin. Oncol., June 1, 2023 RAPT Therapeutics, South San Francisco, CA


MOTY Nominees

Molecule of the Year